Pharmacological Management of Diabetes

Correct Answer

C — Tirzepatide

Rationale

Tirzepatide is classified as a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist — a co-agonist at both incretin receptors in a single synthetic peptide. Semaglutide is a glucagon-like peptide-1 receptor agonist only. Sitagliptin is a dipeptidyl peptidase-4 inhibitor that raises endogenous incretin levels but does not directly agonize either receptor. Metformin is a biguanide.

Correct Answer

A — Tirzepatide agonizes both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor; semaglutide agonizes the glucagon-like peptide-1 receptor only

Rationale

Tirzepatide is a dual agonist at the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Semaglutide is a selective glucagon-like peptide-1 receptor agonist with no meaningful activity at the glucose-dependent insulinotropic polypeptide receptor. Adding glucose-dependent insulinotropic polypeptide receptor agonism is the pharmacological basis for tirzepatide's superior glucose lowering and weight loss compared with semaglutide. Tirzepatide does not agonize the glucagon receptor — that is the mechanism of retatrutide, a pipeline triple agonist. Tirzepatide does not inhibit dipeptidyl peptidase-4.

Correct Answer

D — Triple glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor agonist

Rationale

Retatrutide is classified as a triple receptor agonist targeting glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors simultaneously — a pipeline agent in phase 3 trials. The addition of glucagon receptor agonism beyond the dual agonism of tirzepatide contributes additional energy expenditure and hepatic fat reduction. Tirzepatide is the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist. Cagrilintide is the long-acting amylin analog.

Correct Answer

B — Long-acting amylin analog

Rationale

Cagrilintide is classified as a long-acting amylin analog. Amylin is a peptide co-secreted with insulin from pancreatic beta cells that acts centrally to reduce food intake and slow gastric emptying. Cagrilintide combined with semaglutide (called CagriSema) has shown additive weight loss in trials, suggesting complementary central mechanisms. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist. Semaglutide and liraglutide are glucagon-like peptide-1 receptor agonists. Sitagliptin and linagliptin are dipeptidyl peptidase-4 inhibitors.

Correct Answer

A — Oral non-peptide small-molecule glucagon-like peptide-1 receptor agonist

Rationale

Orforglipron is classified as an oral non-peptide small-molecule glucagon-like peptide-1 receptor agonist — a pipeline agent that does not require an absorption enhancer and may offer simpler oral administration than semaglutide tablets (which require fasting and an absorption enhancer). Oral semaglutide is a peptide-based oral formulation requiring the sodium caprylate absorption enhancer — a different pharmacological category. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist administered as a weekly injection. Dipeptidyl peptidase-4 inhibitors act by preventing incretin degradation, not by directly agonizing the receptor.

Correct Answer

C — Once-weekly subcutaneous injection

Rationale

Tirzepatide is classified as a once-weekly subcutaneous injection, the same dosing schedule as once-weekly semaglutide and dulaglutide. Twice-daily subcutaneous injection is the schedule for exenatide immediate-release. Once-daily subcutaneous injection is the schedule for liraglutide. No glucagon-like peptide-1 receptor agonist or dual agonist currently approved uses a once-monthly injection schedule.

Correct Answer

B — Glucose-dependent insulinotropic polypeptide is responsible for roughly half of the postprandial incretin effect in healthy individuals and its receptor remains largely intact in type 2 diabetes mellitus, making it an additive pharmacological target alongside glucagon-like peptide-1 receptor agonism

Rationale

Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 together account for the postprandial incretin effect, with glucose-dependent insulinotropic polypeptide contributing approximately half. In type 2 diabetes mellitus, the glucagon-like peptide-1 response is blunted but the glucose-dependent insulinotropic polypeptide response is largely preserved. By co-agonizing the glucose-dependent insulinotropic polypeptide receptor alongside the glucagon-like peptide-1 receptor, tirzepatide recruits this intact incretin pathway as an additive source of glucose-dependent insulin secretion amplification — producing greater total incretin effect than glucagon-like peptide-1 receptor agonism alone can achieve. Both receptors signal through Gs to raise cyclic adenosine monophosphate in beta cells, so the mechanism involves additive cyclic adenosine monophosphate accumulation, but the clinical advantage comes from activating a pharmacologically underutilized target, not from using a qualitatively different second messenger. Glucose-dependent insulinotropic polypeptide receptor agonism does not suppress glucagon more potently than glucagon-like peptide-1, and gastric emptying slowing is a glucagon-like peptide-1 receptor effect, not a glucose-dependent insulinotropic polypeptide receptor effect.

Correct Answer

D — Glucose-dependent insulinotropic polypeptide receptor agonism contributes additional satiety signaling through central nervous system pathways that complement and add to glucagon-like peptide-1 receptor-mediated appetite suppression

Rationale

The weight loss advantage of tirzepatide over semaglutide reflects additive or synergistic central nervous system effects of co-agonizing two incretin receptors. Glucose-dependent insulinotropic polypeptide receptors are expressed in hypothalamic and limbic regions involved in energy balance and reward-related feeding behavior, and their activation contributes satiety and appetite-suppressing signals that are distinct from but complementary to those produced by glucagon-like peptide-1 receptor activation. The combined effect on central appetite circuits exceeds what glucagon-like peptide-1 receptor agonism alone achieves. Gastric emptying slowing is a glucagon-like peptide-1 receptor effect; glucose-dependent insulinotropic polypeptide receptor agonism does not add meaningfully to gastric motility slowing. Glucose-dependent insulinotropic polypeptide receptor activation does not lower circulating insulin and does not specifically activate brown adipose thermogenesis as the primary mechanism of superior weight loss.

Correct Answer

A — Glucagon-like peptide-1 receptors are expressed on pro-opiomelanocortin neurons in the arcuate nucleus; receptor activation increases pro-opiomelanocortin neuron firing, releasing alpha-melanocyte-stimulating hormone that promotes satiety and reduces food intake

Rationale

The arcuate nucleus of the hypothalamus contains two opposing neuronal populations governing energy balance. Pro-opiomelanocortin neurons promote satiety when activated, releasing alpha-melanocyte-stimulating hormone that acts on downstream melanocortin receptors to suppress hunger. Agouti-related peptide neurons promote hunger and food-seeking when activated and act as endogenous antagonists of melanocortin signaling. Glucagon-like peptide-1 receptors are expressed on pro-opiomelanocortin neurons, and their activation increases pro-opiomelanocortin neuron firing, tilting the balance toward satiety. Agouti-related peptide neurons are not the site of glucagon-like peptide-1 receptor-mediated appetite suppression — activating those neurons would increase hunger, not suppress it. Dopaminergic nucleus accumbens effects and lateral hypothalamic leptin sensitization are distinct from the arcuate pro-opiomelanocortin mechanism of incretin-based appetite suppression.

Correct Answer

C — Glucagon-like peptide-1 receptor agonism reduces the defended body weight set point pharmacologically; when the drug is stopped, the hypothalamic set point system returns to its pre-treatment level, driving hunger and reducing energy expenditure until the original body weight is restored

Rationale

The concept of a defended body weight set point — the weight the hypothalamic system actively defends by adjusting hunger and energy expenditure — explains why weight loss is so difficult to maintain. Glucagon-like peptide-1 receptor agonism suppresses appetite through arcuate nucleus pro-opiomelanocortin neuron activation, effectively lowering the set point at which hunger signals activate. When the drug is discontinued, this pharmacological signal is removed and the set point returns to its pre-treatment level. The hypothalamic system then drives increased hunger and reduced energy expenditure until the original body weight is restored — producing complete weight regain even without any behavioral change. This is why these agents function more like antihypertensives (requiring continuous therapy) than antibiotics (providing a fixed course of treatment). Gastric emptying normalization, receptor downregulation, and lean mass repletion are separate considerations that do not account for the complete and rapid weight regain observed after discontinuation.

Correct Answer

B — Tirzepatide demonstrated superiority over dulaglutide in reducing major adverse cardiovascular events, establishing tirzepatide as the first dual agonist with proven cardiovascular superiority over an active comparator

Rationale

The SURPASS-CVOT trial (2025) compared tirzepatide with dulaglutide — an active glucagon-like peptide-1 receptor agonist comparator with established cardiovascular benefit — in patients with type 2 diabetes mellitus and established cardiovascular disease. Tirzepatide demonstrated superiority over dulaglutide for major adverse cardiovascular event reduction, establishing that dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonism produces greater cardiovascular protection than glucagon-like peptide-1 receptor agonism alone. This makes tirzepatide the first agent in its class to achieve cardiovascular superiority versus an active comparator rather than merely demonstrating safety versus placebo. Tirzepatide showed no cardiovascular safety concern in this trial.

Correct Answer

D — Tirzepatide reduces hepatic lipotoxicity through substantial weight loss that decreases hepatic fat delivery, combined with direct anti-inflammatory effects of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor signaling in hepatocytes

Rationale

Tirzepatide's benefit in metabolic dysfunction-associated steatohepatitis involves two complementary mechanisms. First, the substantial weight loss produced by dual incretin receptor agonism reduces the delivery of free fatty acids from adipose tissue to the liver, decreasing hepatic lipid accumulation and lipotoxicity — the primary driver of hepatocellular injury and inflammation in this condition. Second, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors are expressed in hepatocytes and their activation has direct anti-inflammatory effects that reduce hepatic inflammation and may slow fibrosis progression. Tirzepatide does not activate peroxisome proliferator-activated receptor gamma (that is the mechanism of thiazolidinediones), does not inhibit hepatic lipase, and does not suppress gluconeogenesis through glucose-dependent insulinotropic polypeptide receptor-mediated adenosine monophosphate-activated protein kinase activation as its primary hepatic mechanism.

Correct Answer

A — She will regain most or all of the lost weight because the hypothalamic set point defended before treatment returns when the pharmacological signal is removed, driving increased hunger and reduced energy expenditure

Rationale

Clinical trial data from semaglutide withdrawal studies show that weight regain after stopping therapy is rapid and nearly complete — patients regain on average 65 to 85 percent of lost weight within 12 months. This is because the weight loss does not reflect a permanent change in physiology but rather ongoing pharmacological suppression of the hypothalamic defended weight set point. When the drug is removed, the set point reverts to its pre-treatment level, and the hypothalamic system drives increased hunger signals and reduced energy expenditure to restore the original defended weight. The treatment duration — whether 14 months or longer — does not permanently reset the set point. Caloric restriction cannot substitute for the pharmacological signal that was suppressing appetite. The return of normal gastric emptying does not produce weight loss.

Correct Answer

C — Tirzepatide contains the glucagon-like peptide-1 receptor agonist component, and glucagon-like peptide-1 receptors expressed on thyroid C cells were shown in rodent studies to produce C-cell hyperplasia with sustained activation; the contraindication applies to all drugs activating this receptor

Rationale

Tirzepatide carries the same medullary thyroid carcinoma and multiple endocrine neoplasia type 2 contraindication as pure glucagon-like peptide-1 receptor agonists because it shares the glucagon-like peptide-1 receptor agonist component. Thyroid C cells express glucagon-like peptide-1 receptors, and sustained activation in rodent studies produced dose-dependent C-cell hyperplasia and tumors — the basis for the class-wide contraindication. This risk, while unconfirmed in humans, applies to any agent that activates the glucagon-like peptide-1 receptor, including tirzepatide. Glucose-dependent insulinotropic polypeptide receptors are not expressed on thyroid C cells in a way that drives the contraindication, and medullary thyroid carcinoma cells are not known to specifically overexpress the glucose-dependent insulinotropic polypeptide receptor as a relevant pharmacological target. No human trial has confirmed elevated calcitonin as a clinical signal from the glucose-dependent insulinotropic polypeptide receptor component.

Correct Answer

B — Tirzepatide adds glucose-dependent insulinotropic polypeptide receptor agonism to glucagon-like peptide-1 receptor agonism, engaging a second central satiety pathway that semaglutide alone does not activate, producing additive appetite suppression

Rationale

This patient has had a suboptimal weight loss response to semaglutide despite good glycemic improvement, a common clinical scenario. Tirzepatide produces substantially greater weight loss than semaglutide in head-to-head trials — approximately double in SURPASS-2 — because dual agonism at the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor engages a second central appetite-suppressing pathway. The glucose-dependent insulinotropic polypeptide receptor is expressed in hypothalamic and limbic appetite circuits and its activation adds to the satiety signaling produced by glucagon-like peptide-1 receptor activation. Her intact glucose-dependent insulinotropic polypeptide receptor response — which is preserved in type 2 diabetes mellitus even when the glucagon-like peptide-1 response is blunted — makes this additional target pharmacologically exploitable. Tirzepatide does not have higher glucagon-like peptide-1 receptor affinity than semaglutide, does not add glucagon receptor agonism (that is retatrutide), and does not produce greater gastric emptying slowing as the primary weight loss mechanism.

Correct Answer

D — Tirzepatide

Rationale

The SYNERGY-NASH trial established tirzepatide as the pharmacological agent with the most robust evidence for metabolic dysfunction-associated steatohepatitis resolution — achieving histological resolution in 62 percent of patients versus 19 percent on placebo, with improvement in fibrosis in 55 percent. This trial led to the first regulatory approval of a medication specifically for metabolic dysfunction-associated steatohepatitis. The mechanism involves dual reduction of hepatic lipotoxicity through substantial weight loss and direct anti-inflammatory glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor signaling in hepatocytes. Sitagliptin has no established evidence for metabolic dysfunction-associated steatohepatitis resolution. Empagliflozin reduces hepatic fat but does not have comparable histological trial evidence for this indication. Liraglutide has shown modest metabolic dysfunction-associated steatohepatitis benefit in smaller trials but tirzepatide's SYNERGY-NASH data are substantially stronger.

Correct Answer

A — Reduce the dose back to 5 mg weekly and attempt re-escalation more slowly after symptoms resolve

Rationale

This patient tolerated tirzepatide 5 mg with mild nausea, indicating he is not intolerant to the drug class — his severe symptoms began after escalation to 10 mg, identifying the higher dose as the precipitant. The gastrointestinal adverse effects of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonists are dose-dependent and peak during escalation as gastric emptying slows further. The appropriate management is dose de-escalation to the last tolerated dose (5 mg), allowing symptoms to resolve, then attempting re-escalation at a slower pace. Permanent discontinuation is not warranted when the patient tolerated the prior dose without severe symptoms. Adding a proton pump inhibitor does not address the mechanism — these symptoms reflect gastric emptying delay, not acid hypersecretion. Semaglutide also slows gastric emptying through glucagon-like peptide-1 receptor activation, and the low blood glucose readings indicate adequate drug effect is already present; switching agents does not resolve a dose-related tolerability problem.

Correct Answer

C — Tirzepatide is appropriate because the SUMMIT trial demonstrated that tirzepatide reduced cardiovascular death and worsening heart failure events in patients with heart failure with preserved ejection fraction and obesity, the population this patient represents

Rationale

The SUMMIT trial evaluated tirzepatide specifically in patients with heart failure with preserved ejection fraction and obesity and demonstrated reduction in the composite of cardiovascular death and worsening heart failure events, along with improved exercise capacity and quality of life. This patient — with heart failure with preserved ejection fraction and a body mass index of 38 — falls precisely into the trial population, making tirzepatide an evidence-based choice. Heart failure with preserved ejection fraction is strongly associated with obesity and represents one of the few disease states where pharmacological weight reduction has demonstrated meaningful cardiac benefit. The EMPEROR-Reduced trial studied empagliflozin in heart failure with reduced ejection fraction, not glucagon-like peptide-1 receptor agonists in heart failure with preserved ejection fraction. Tirzepatide does not activate peroxisome proliferator-activated receptor gamma — that is the mechanism of thiazolidinediones. Tirzepatide does not cause sodium retention; the glucose-dependent insulinotropic polypeptide receptor does not drive renal sodium reabsorption in the way that thiazolidinediones do.